Net Income (Loss) Attributable to Parent in USD of Mersana Therapeutics, Inc. from 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Mersana Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2015 to Q3 2025.
  • Mersana Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$7.55M, a 34.4% increase year-over-year.
  • Mersana Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$70.1M, a 6.08% increase year-over-year.
  • Mersana Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$69.2M, a 59.7% increase from 2023.
  • Mersana Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$172M, a 15.9% increase from 2022.
  • Mersana Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$204M, a 20.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Mersana Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$70.1M -$7.55M +$3.96M +34.4% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$74M -$24.3M -$28K -0.12% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$74M -$24.1M -$4.82M -25% 01 Jan 2025 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$69.2M -$14.1M +$5.43M +27.8% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025
Q3 2024 -$74.6M -$11.5M +$30.2M +72.4% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$105M -$24.3M +$30M +55.3% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$135M -$19.3M +$36.9M +65.6% 01 Jan 2024 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$172M -$19.5M +$25.4M +56.5% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 -$197M -$41.7M +$18.2M +30.4% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 -$215M -$54.3M -$2.09M -4% 01 Apr 2023 30 Jun 2023 10-Q 13 Nov 2024
Q1 2023 -$213M -$56.2M -$8.91M -18.8% 01 Jan 2023 31 Mar 2023 10-Q 13 Nov 2024
Q4 2022 -$204M -$44.9M +$4.06M +8.29% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025
Q3 2022 -$208M -$59.8M -$14.3M -31.5% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023
Q2 2022 -$194M -$52.2M -$11.3M -27.6% 01 Apr 2022 30 Jun 2022 10-Q 07 Nov 2023
Q1 2022 -$183M -$47.3M -$12.6M -36.2% 01 Jan 2022 31 Mar 2022 10-Q 07 Nov 2023
Q4 2021 -$170M -$49M -$20.1M -69.8% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024
Q3 2021 -$150M -$45.5M -$23M -102% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$127M -$40.9M -$21.1M -107% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$106M -$34.7M -$17.8M -105% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 -$88M -$28.8M -$12.6M -77.5% 01 Oct 2020 31 Dec 2020 10-Q 09 Nov 2021
Q3 2020 -$75.4M -$22.5M -$5.7M -33.9% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$69.8M -$19.8M -$2.72M -15.9% 01 Apr 2020 30 Jun 2020 10-Q 09 Nov 2021
Q1 2020 -$67M -$16.9M -$38.8M -177% 01 Jan 2020 31 Mar 2020 10-Q 09 Nov 2021
Q4 2019 -$28.2M -$16.2M +$6.19M +27.6% 01 Oct 2019 31 Dec 2019 10-K 26 Feb 2021
Q3 2019 -$34.4M -$16.8M +$277K +1.62% 01 Jul 2019 30 Sep 2019 10-K 26 Feb 2021
Q2 2019 -$34.7M -$17.1M -$4.72M -38.2% 01 Apr 2019 30 Jun 2019 10-K 26 Feb 2021
Q1 2019 -$30M $21.9M +$34.3M 01 Jan 2019 31 Mar 2019 10-K 26 Feb 2021
Q4 2018 -$64.3M -$22.4M -$8.46M -60.6% 01 Oct 2018 31 Dec 2018 10-K 28 Feb 2020
Q3 2018 -$55.8M -$17.1M -$9.34M -121% 01 Jul 2018 30 Sep 2018 10-K 28 Feb 2020
Q2 2018 -$46.5M -$12.4M -$3.41M -38.1% 01 Apr 2018 30 Jun 2018 10-K 28 Feb 2020
Q1 2018 -$43M -$12.4M -$4.34M -53.9% 01 Jan 2018 31 Mar 2018 10-K 28 Feb 2020
Q4 2017 -$38.7M -$14M -$15.2M -1209% 01 Oct 2017 31 Dec 2017 10-K 08 Mar 2019
Q3 2017 -$23.5M -$7.73M -$1.9M -32.5% 01 Jul 2017 30 Sep 2017 10-K 08 Mar 2019
Q2 2017 -$21.6M -$8.95M -$5.18M -138% 01 Apr 2017 30 Jun 2017 10-K 08 Mar 2019
Q1 2017 -$16.4M -$8.06M -$2.71M -50.5% 01 Jan 2017 31 Mar 2017 10-K 08 Mar 2019
Q4 2016 -$13.7M $1.26M 01 Oct 2016 31 Dec 2016 10-K 28 Mar 2018
Q3 2016 -$5.84M 01 Jul 2016 30 Sep 2016 10-K 28 Mar 2018
Q2 2016 -$3.77M 01 Apr 2016 30 Jun 2016 10-K 28 Mar 2018
Q1 2016 -$5.36M 01 Jan 2016 31 Mar 2016 10-K 28 Mar 2018

Mersana Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$69.2M +$102M +59.7% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025
2023 -$172M +$32.5M +15.9% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025
2022 -$204M -$34.2M -20.1% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025
2021 -$170M -$82M -93.2% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024
2020 -$88M -$59.8M -212% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023
2019 -$28.2M +$36M +56.1% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022
2018 -$64.3M -$25.6M -66% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021
2017 -$38.7M -$25M -183% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020
2016 -$13.7M +$2.73M +16.6% 01 Jan 2016 31 Dec 2016 10-K 08 Mar 2019
2015 -$16.4M 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.